Download PDF
Thromb Haemost 2001; 85(02): 250-255
DOI: 10.1055/s-0037-1615705
Review Article
Schattauer GmbH

Whole Blood Tissue Factor Procoagulant Activity Remains Detectable during Severe Aplasia following Bone Marrow and Peripheral Blood Stem Cell Transplantation

Muhit Ozcan
1   Department of Hematology, University of Ankara Medical School, Ibni Sina Hospital, Ankara, Turkey
,
Colleen T. Morton
2   Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
,
Anna Solovey
2   Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
,
Luke Dandelet
2   Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
,
Ronald R. Bach
3   Research Service, Veterans’ Administration Hospital, Minneapolis, MN, USA
,
Robert P. Hebbel
2   Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
,
Arne Slungaard
2   Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
,
Nigel S. Key
2   Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
› Author AffiliationsSupported by grants R29-HL55219 (to N.S.K.) and MO1-RR00400 from the National Center for Research Resources, the National Institutes of Health
Further Information

Publication History

Received 29 May 2000

Accepted after resubmission 30 August 2000

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

Using a novel whole blood assay, we recently demonstrated that tissue factor procoagulant activity (TF PCA) is present in normal individuals. Preliminary experiments suggested that this activity is localized in the mononuclear cell fraction. Postulating that whole blood TF PCA would therefore be undetectable when monocytes and neutrophils are absent from peripheral blood, we assayed TF PCA during the peri-transplant period in 15 consecutive patients undergoing allogeneic (n = 12) or autologous (n = 3) bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT). Baseline (pre-transplant) mean TF PCA was higher in patients compared to normal controls (P <0.005). Unexpectedly, although TF PCA during the period of profound aplasia was significantly reduced compared to baseline (p <0.05), fully 55% of the initial activity remained detectable. During the engraftment phase, TF PCA returned to pre-transplant levels, with a linear correlation between monocyte counts and TF PCA (r = 0.63). In contrast to normal whole blood, incubation of aplastic samples with E. Coli lipopolysaccharide ex vivo failed to induce TF PCA. Throughout the period of study – but especially during the aplastic phase – the absolute number of circulating endothelial cells (CECs) that were TF antigen-positive was increased compared to normals (P <0.001). However, removal of these cells from whole blood samples failed to significantly diminish total TF PCA indicating that CECs alone could not account for the detectable TF PCA during aplasia. We conclude that neither circulating mature myelo-monocytic cells nor endothelial cells can account for all the functionally intact TF in peripheral blood. Further studies are needed to identify the other source(s) of TF PCA.

Keywords

Tissue factor - whole blood - bone marrow transplantation - bone marrow aplasia
 

  • References

  • 1 Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a “Prima Ballerina”. Thromb Haemost 1995; 74: 7-17.
    PubMedGoogle Scholar
  • 2 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Path 1989; 134: 1087-97.
    PubMedGoogle Scholar
  • 3 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci (USA) 1989; 86: 2839-93.
    CrossrefPubMedGoogle Scholar
  • 4 Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties: modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989; 264: 20705-13.
    PubMedGoogle Scholar
  • 5 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9: 2752-5.
    CrossrefPubMedGoogle Scholar
  • 6 Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant activity while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-4.
    CrossrefPubMedGoogle Scholar
  • 7 Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53: 231-41.
    CrossrefPubMedGoogle Scholar
  • 8 Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-64.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Osterud B, Flaegstad T. Increased thromboplastin activity in monocytes of patients with meningococcal infections: related to unfavourable prognosis. Thromb Haemost 1983; 49: 5-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant pheno-type of human breast disease. Nature Med 1996; 2 (Suppl. 02) 209-15.
    CrossrefPubMedGoogle Scholar
  • 11 Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor. Am J Path 1998; 152 (Suppl. 02) 399-411.
    PubMedGoogle Scholar
  • 12 Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Brit J. Haem 1994; 87: 343-7.
    CrossrefPubMedGoogle Scholar
  • 13 Fukuda C, Iijima K, Nakamura K. Measuring tissue factor (factor III) activity in plasma. Clin Chem 1989; 35 (Suppl. 09) 1897-900.
    PubMedGoogle Scholar
  • 14 Francis JL, Carvalho M, Francis DA. The clinical value of tissue factor assays. Blood Coagul Fibrinol 1995; 6 (Suppl. 01) S37-44.
    CrossrefPubMedGoogle Scholar
  • 15 Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-23.
    PubMedGoogle Scholar
  • 16 Giesen PLA, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci (USA) 1999; 96: 2311-15.
    CrossrefPubMedGoogle Scholar
  • 17 Solovey A, Lin Y, Browne PV, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 1584-90.
    CrossrefPubMedGoogle Scholar
  • 18 Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998; 101: 1899-904.
    CrossrefPubMedGoogle Scholar
  • 19 Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Brit J. Haematol 1975; 30 (Suppl. 03) 311-6.
    CrossrefPubMedGoogle Scholar
  • 20 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79 (Suppl. 01) 124-30.
    CrossrefPubMedGoogle Scholar
  • 21 Gordon SG, Mielicki WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinol 1997; 8: 73-86.
    CrossrefPubMedGoogle Scholar
  • 22 Carlsen E, Stinessen MB, Prydz H. Differential effect of α-interferon and γ-interferon on thromboplastin response in monocytes and endothelial cells. Clin Exp Immunol 1987; 70: 471-8.
    PubMedGoogle Scholar
  • 23 Zuckerman SH, Surprenant YM. Induction of endothelial cell/macrophage procoagulant activity:synergistic stimulation by gamma interferon and granulocytic-macrophage colony stimulating factor. Thromb Haemost 1989; 61: 178-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Bastida E, Ordinas A, Escolar G, Jamieson GA. Tissue factor in micro-vesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 1984; 1: 177-84.
    PubMedGoogle Scholar
  • 25 Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM. Tumor shedding and coagulation. Science (Wash DC) 1981; 212: 923-4.
    CrossrefPubMedGoogle Scholar
  • 26 Hair GA, Padula S, Zeff R, Schmeiezl M, Contrino J, Kreutzer DL, de Moerloose P, Boyd AW, Stanley I, Burgess AW, Rickles FR. Tissue factor expression in human leukemic cells. Leuk Res 1996; 20: 1-11.
    CrossrefPubMedGoogle Scholar
  • 27 Carr JM, Dvorak AM, Dvorak HF. Circulating membrane vesicles in leukemic blood. Cancer Res 1985; 45: 5944-51.
    PubMedGoogle Scholar
  • 28 Rickles FR, Hair GA, Zeff RA, Lee E, Bona RD. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost 1995; 74: 391-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995-9.
    CrossrefPubMedGoogle Scholar
  • 30 Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-6.
    PubMedGoogle Scholar
  • 31 Maynard JR, Dreyer BE, Stemerman MB, Pitlick FA. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood 1977; 50 (Suppl. 03) 387-96.
    PubMedGoogle Scholar